vs

Side-by-side financial comparison of Exodus Movement, Inc. (EXOD) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $29.4M, roughly 1.3× Exodus Movement, Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -181.0%, a 177.3% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -34.4%). GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-25.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 0.6%).

Exodus is a cryptocurrency wallet available on desktop and mobile platforms. It was founded in 2015 by JP Richardson and Daniel Castagnoli. Exodus wallet supports digital assets including Bitcoin, Ethereum, and Solana. It is available on Windows, macOS, Linux, iOS, Android, and as a browser extension.

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

EXOD vs GYRE — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.3× larger
GYRE
$37.2M
$29.4M
EXOD
Growing faster (revenue YoY)
GYRE
GYRE
+67.8% gap
GYRE
33.4%
-34.4%
EXOD
Higher net margin
GYRE
GYRE
177.3% more per $
GYRE
-3.7%
-181.0%
EXOD
More free cash flow
GYRE
GYRE
$20.1M more FCF
GYRE
$-5.8M
$-25.8M
EXOD
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
0.6%
EXOD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EXOD
EXOD
GYRE
GYRE
Revenue
$29.4M
$37.2M
Net Profit
$-53.2M
$-1.4M
Gross Margin
95.3%
Operating Margin
-226.9%
0.3%
Net Margin
-181.0%
-3.7%
Revenue YoY
-34.4%
33.4%
Net Profit YoY
-179.5%
-340.1%
EPS (diluted)
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXOD
EXOD
GYRE
GYRE
Q4 25
$29.4M
$37.2M
Q3 25
$30.3M
$30.6M
Q2 25
$25.8M
$26.8M
Q1 25
$36.0M
$22.1M
Q4 24
$44.8M
$27.9M
Q3 24
$20.1M
$25.5M
Q2 24
$22.3M
$25.2M
Q1 24
$29.1M
$27.2M
Net Profit
EXOD
EXOD
GYRE
GYRE
Q4 25
$-53.2M
$-1.4M
Q3 25
$17.0M
$5.9M
Q2 25
$37.7M
$1.6M
Q1 25
$-12.9M
$3.7M
Q4 24
$66.9M
$569.0K
Q3 24
$843.0K
$2.9M
Q2 24
$-9.6M
$4.5M
Q1 24
$54.8M
$9.9M
Gross Margin
EXOD
EXOD
GYRE
GYRE
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
43.7%
96.2%
Q2 24
51.7%
96.9%
Q1 24
63.2%
96.4%
Operating Margin
EXOD
EXOD
GYRE
GYRE
Q4 25
-226.9%
0.3%
Q3 25
66.9%
22.7%
Q2 25
8.1%
Q1 25
-60.4%
10.3%
Q4 24
2.4%
Q3 24
-0.3%
16.6%
Q2 24
-66.1%
12.7%
Q1 24
29.7%
Net Margin
EXOD
EXOD
GYRE
GYRE
Q4 25
-181.0%
-3.7%
Q3 25
56.2%
19.4%
Q2 25
145.8%
5.9%
Q1 25
-35.8%
16.9%
Q4 24
149.4%
2.0%
Q3 24
4.2%
11.2%
Q2 24
-43.1%
18.0%
Q1 24
188.5%
36.6%
EPS (diluted)
EXOD
EXOD
GYRE
GYRE
Q4 25
$-0.01
Q3 25
$0.03
Q2 25
$0.00
Q1 25
$0.00
Q4 24
$0.00
Q3 24
$0.01
Q2 24
$0.01
Q1 24
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXOD
EXOD
GYRE
GYRE
Cash + ST InvestmentsLiquidity on hand
$4.9M
$52.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$247.4M
$106.0M
Total Assets
$266.8M
$166.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXOD
EXOD
GYRE
GYRE
Q4 25
$4.9M
$52.4M
Q3 25
$50.5M
$60.0M
Q2 25
$52.9M
$54.4M
Q1 25
$59.8M
$29.9M
Q4 24
$37.9M
$26.7M
Q3 24
$26.5M
$25.1M
Q2 24
$27.8M
$25.1M
Q1 24
$21.0M
$37.4M
Stockholders' Equity
EXOD
EXOD
GYRE
GYRE
Q4 25
$247.4M
$106.0M
Q3 25
$296.7M
$101.9M
Q2 25
$277.1M
$92.0M
Q1 25
$241.5M
$68.1M
Q4 24
$257.5M
$63.3M
Q3 24
$191.2M
$63.2M
Q2 24
$190.8M
$60.4M
Q1 24
$199.1M
$56.6M
Total Assets
EXOD
EXOD
GYRE
GYRE
Q4 25
$266.8M
$166.1M
Q3 25
$338.5M
$159.4M
Q2 25
$313.7M
$152.6M
Q1 25
$263.2M
$129.8M
Q4 24
$288.0M
$125.4M
Q3 24
$211.6M
$125.2M
Q2 24
$211.6M
$120.9M
Q1 24
$225.4M
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXOD
EXOD
GYRE
GYRE
Operating Cash FlowLast quarter
$-25.6M
$-5.6M
Free Cash FlowOCF − Capex
$-25.8M
$-5.8M
FCF MarginFCF / Revenue
-87.9%
-15.5%
Capex IntensityCapex / Revenue
0.9%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-42.3M
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXOD
EXOD
GYRE
GYRE
Q4 25
$-25.6M
$-5.6M
Q3 25
$-4.8M
$4.7M
Q2 25
$-5.3M
$2.1M
Q1 25
$-6.2M
$-129.0K
Q4 24
$-12.0M
$-2.8M
Q3 24
$-4.9M
$1.7M
Q2 24
$-2.4M
$-5.5M
Q1 24
$450.0K
$2.9M
Free Cash Flow
EXOD
EXOD
GYRE
GYRE
Q4 25
$-25.8M
$-5.8M
Q3 25
$-4.8M
$4.0M
Q2 25
$-5.4M
$1.8M
Q1 25
$-6.2M
$-251.0K
Q4 24
$-12.3M
$-2.8M
Q3 24
$-4.9M
$1.0M
Q2 24
$-2.4M
$-6.9M
Q1 24
$300.0K
$2.7M
FCF Margin
EXOD
EXOD
GYRE
GYRE
Q4 25
-87.9%
-15.5%
Q3 25
-16.0%
13.1%
Q2 25
-20.7%
6.8%
Q1 25
-17.3%
-1.1%
Q4 24
-27.5%
-10.1%
Q3 24
-24.5%
4.1%
Q2 24
-10.8%
-27.5%
Q1 24
1.0%
9.8%
Capex Intensity
EXOD
EXOD
GYRE
GYRE
Q4 25
0.9%
0.4%
Q3 25
0.1%
2.2%
Q2 25
0.4%
1.0%
Q1 25
0.1%
0.6%
Q4 24
0.6%
0.2%
Q3 24
0.2%
2.7%
Q2 24
0.2%
5.8%
Q1 24
0.5%
0.9%
Cash Conversion
EXOD
EXOD
GYRE
GYRE
Q4 25
Q3 25
-0.28×
0.79×
Q2 25
-0.14×
1.32×
Q1 25
-0.03×
Q4 24
-0.18×
-4.85×
Q3 24
-5.80×
0.60×
Q2 24
-1.21×
Q1 24
0.01×
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXOD
EXOD

Exchange Aggregation$26.6M90%
Other$2.8M10%

GYRE
GYRE

Segment breakdown not available.

Related Comparisons